PRECIGEN, INC.

Key metrics

Financial performance

Over the last 9 fiscal years PRECIGEN, INC.'s revenue declined from $190.93M to $9.68M, a compound annual decline rate of 28.2%. Net profit margin compressed from -97.7% to -2587.8% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,273 filings)

Recent press releases

• Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years2026-05-30

  Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years | Precigen

• Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States2026-05-27

  Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States | Precigen

• Precigen Participate Fireside Chats Jp Morgan And Goldman Sachs2026-05-26

  Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference | Precigen

• Precigen Reports First Quarter 2026 Financial Results and Business Updates2026-05-13

  Precigen Reports First Quarter 2026 Financial Results and Business Updates | Precigen

• Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 132026-05-07

  Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 | Precigen

Similar companies

The largest companies sharing PRECIGEN, INC.'s SEC industry classification (pharmaceutical preparations).